News

Enara Bio highlights Dark Antigens™ as a novel class of targets for developing targeted immunotherapies against solid tumors Enara Bio highlights Dark Antigens™ as a novel class of targets for developing targeted immunotherapies against solid tumors Enara Bio’s unique approach identifying Dark Antigen™ candidates and cognate T cells in non-small-cell lung cancer and melanoma detailed in two posters to be presented at the 37th Society for Immunotherapy of Cancer Annual Meeting Enara Bio’s Dark Antigen presentations from the 37th Society for Immunotherapy of Cancer Annual Meeting Enara Bio’s Dark Antigen presentations from the 37th Society for Immunotherapy of Cancer Annual Meeting ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research Enara Bio’s presentation on development of an MR1-targeting T cell therapy from the 12th International CD1-MR1 EMBO Meeting Enara Bio’s presentation on development of an MR1-targeting T cell therapy from the 12th International CD1-MR1 EMBO Meeting Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting Enara Bio announces the appointment of T-cell therapy leader 
Dr. Sophie Papa as Chief Medical Officer Enara Bio announces the appointment of T-cell therapy leader 
Dr. Sophie Papa as Chief Medical Officer Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist. Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director Enara Bio participates in Boehringer Ingelheim’s 
“Taking Cancer On” podcast series Enara Bio participates in Boehringer Ingelheim’s 
“Taking Cancer On” podcast series Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today. Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June. Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research